ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$16.53 USD
+0.11 (0.67%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $16.54 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Company Summary
San Diego, CA-based Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address unmet medical needs in CNS disorders and rare diseases.
Acadia’s Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease (PD) psychosis. The drug was launched in May 2016. Acadia’s top line also comprises sales of Daybue (trofinetide) in the United States.
In March 2023, Acadia announced that the FDA approved trofinetide for the treatment of Rett syndrome in adult and pediatric patients ...
Company Summary
San Diego, CA-based Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address unmet medical needs in CNS disorders and rare diseases.
Acadia’s Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease (PD) psychosis. The drug was launched in May 2016. Acadia’s top line also comprises sales of Daybue (trofinetide) in the United States.
In March 2023, Acadia announced that the FDA approved trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The drug is marketed in the United States under the brand name, Daybue. Acadia also received a Rare Pediatric Disease Priority Review Voucher from the FDA, along with the approval of Daybue, which can be used to obtain priority review for a subsequent application. The approval of Daybue is generating incremental revenues for the company, thereby boosting the top line.
Notably, following the March 2024 setback, Acadia has decided not to pursue any further clinical studies with pimavanserin.
Meanwhile, in July 2023, Acadia extended its existing license agreement with Australian biopharmaceutical company Neuren Pharmaceuticals Limited, acquiring rights to market trofinetide outside North America along with exclusive global rights to Neuren’s development candidate, NNZ-2591, in Rett syndrome and Fragile X syndrome.
Acadia also added a new late-stage candidate, carbetocin nasal spray (ACP-101), to its rare disease portfolio. The investigational, intranasal formulation of ACP-101 is being evaluated for the treatment of hyperphagia in Prader-Willi Syndrome (PWS).
Acadia recognized revenues, mainly comprising Nuplazid U.S. sales worth $726.4 million in 2023 compared with $517.2 million in 2022.
General Information
ACADIA Pharmaceuticals Inc
12830 El Camino Real Suite 400
SAN DIEGO, CA 92130
Phone: 858-558-2871
Fax: 858-558-2872
Web: http://www.acadia-pharm.com
Email: ir@acadia-pharm.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.11 |
Current Year EPS Consensus Estimate | 0.52 |
Estimated Long-Term EPS Growth Rate | 57.70 |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 16.42 |
52 Week High | 32.59 |
52 Week Low | 14.55 |
Beta | 0.40 |
20 Day Moving Average | 1,068,619.38 |
Target Price Consensus | 24.89 |
4 Week | 4.72 |
12 Week | 0.31 |
YTD | -47.56 |
4 Week | 2.10 |
12 Week | -3.75 |
YTD | -56.22 |
Shares Outstanding (millions) | 165.88 |
Market Capitalization (millions) | 2,723.69 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 31.70 |
Trailing 12 Months | 91.22 |
PEG Ratio | 0.55 |
vs. Previous Year | 1,900.00% |
vs. Previous Quarter | 100.00% |
vs. Previous Year | 46.44% |
vs. Previous Quarter | 17.55% |
Price/Book | 5.25 |
Price/Cash Flow | NA |
Price / Sales | 3.06 |
6/30/24 | 6.89 |
3/31/24 | -0.41 |
12/31/23 | -15.67 |
6/30/24 | 3.88 |
3/31/24 | -0.24 |
12/31/23 | -9.15 |
6/30/24 | 2.16 |
3/31/24 | 2.04 |
12/31/23 | 2.42 |
6/30/24 | 1.95 |
3/31/24 | 1.86 |
12/31/23 | 2.28 |
6/30/24 | 3.43 |
3/31/24 | -0.21 |
12/31/23 | -8.44 |
6/30/24 | 3.43 |
3/31/24 | -0.21 |
12/31/23 | -8.44 |
6/30/24 | 5.14 |
3/31/24 | 1.83 |
12/31/23 | -7.03 |
6/30/24 | 3.13 |
3/31/24 | 2.81 |
12/31/23 | 2.63 |
6/30/24 | 1.55 |
3/31/24 | 1.97 |
12/31/23 | 2.32 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |